Auro Laboratories (530233.BO) Stock Price

Auro Laboratories Price

CLOSED
231.10
​
Market closed

Revenue at Auro Laboratories has contracted by 2.8% per year over the past 13 years to 307.40 M INR. Earnings per share have grown at 12.4% per year over the last 13 years. For Auro Laboratories, the net margin of 11.5% is up versus 5.6% a few years ago.

Auro Laboratories stock price

Access this data via the Eulerpool API

Auro Laboratories business model & stock analysis

Auro Laboratories Ltd. engages in the manufacture of active pharmaceutical ingredients, intermediates and generic formulations. The company is headquartered in Mumbai, Maharashtra. The firm operates through the Pharmaceuticals segment. The company offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. The company also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The firm has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.

Frequently asked questions about Auro Laboratories

Converted at the current exchange rate, the Auro Laboratories share trades at 2.13 EUR (231.10 INR).

The revenue of Auro Laboratories is 307.40 M INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Auro Laboratories is 35.33 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Auro Laboratories is currently 40.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Auro Laboratories stock.

The price-to-sales ratio (P/S) of Auro Laboratories is currently 4.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Auro Laboratories stock.

The Eulerpool Quality Score for Auro Laboratories is 3/10.

The ISIN of Auro Laboratories is INE292C01011. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Auro Laboratories is 530233.BO. The ticker symbol is used to trade Auro Laboratories shares on the stock exchange.

Fair ValueTerminal
201.06 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website aurolabs.com
Country
Currency
INR
Initial public offering
Mar 7, 1995
ISIN
INE292C01011
Cusip
Y04529114
Market capitalization
1.44 B INRSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
23.63
P/B Ratio
3.11
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
3.94 %
Last updated Oct 10, 2026, 6:08 AM

Auro Laboratories Peer Group

Auro Laboratories FIGI

ARL:IN · BBG000F7VLC3ARL:IB · BBG000F7VM04